Search Results

Araim Pharmaceuticals, Inc. is pleased to announce the appointment of Ferdinand “Ferry” Breedveld, MD, PhD, the Chairman of the Board at Araim, as the organization’s acting Chief Executive Officer.

Araim Pharmaeuticals, Inc. is proud to announce that founder Anthony Cerami, PhD, MD (Hon) has been awarded the Paul Ehrlich and Ludwig Darmstaedter Prize for 2018.

Cibinetide, the lead compound of Araim Pharmaceuticals, Inc., a clinical stage biotechnology company pioneering the development of innate repair receptor activator platform technology, has recently been shown to improve the efficacy of endothelial colony forming cell transplantation to repair the vasculature in the retina.

Experiment Demonstrates Cibinetide (ARA 290) Significantly Reduces Frailty and Decline in Heart Function Associated with Aging in Animal Models [02-May-2018] New Research Shows Promising Signs in Anti-Aging for Araim Pharmaceuticals Experiment Demonstrates Cibinetide (ARA 290) Significantly Reduces Frailty and De

Araim Pharma today announced the publication of preclinical research performed at the University of Messina, Italy, demonstrating the ability of their lead compound cibinetide to improve wound healing in a diabetic mouse model by accelerating wound closure, promoting blood vessel growth, and increasing the strength of the healing tissue.